Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metast... by Matthew Burge, David Goldstein, Andrew Haydon, Nick Pavlakis, Charlotte Lemech, Edward Hammond, Darryn Bampton, Keith Dredge, Michael P Brown, Andrew Clouston, Nigel J Waterhouse, Amanda C Stanley, Lucie Leveque-El Mouttie, Grace M Chojnowski

Get full text

Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination by Maaweya Awadalla, Halah Z. AlRawi, Rahaf A. Henawi, Fawziya Barnawi, Haitham Alkadi, Ahmed Alyami, Ammar Alsughayir, Alyazeed S. Alsaif, Ayman Mubarak, Wael Alturaiki, Bandar Alosaimi

“…IntroductionThe durability of Hybrid immunity induced by natural infection and/or COVID-19 vaccines and evidence supporting further booster vaccination are crucial factors for pandemic response, yet remain poorly understood.MethodsWe measured the durability of immune response and neutralizing capacity of antibodies following Homologous/Heterologous vaccination by mRNA-based vaccines (Pfizer-BioNTech BNT162b2) or (Moderna mRNA-1273) and viral vector-based vaccines (ChAdox1 nCoV-19-Oxford-AstraZeneca) in infected and non-infected patients. …”
Get full text

Recombinant Anti-PF4 Antibodies Derived from Patients with Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Facilitate Research and Laboratory Diagnosis of VITT by Luisa Müller, Venkata A. S. Dabbiru, Lucy Rutten, Rinke Bos, Roland Zahn, Stefan Handtke, Thomas Thiele, Marta Palicio, Olga Esteban, Marta Broto, Tom Paul Gordon, Andreas Greinacher, Jing Jing Wang, Linda Schönborn

“…Six different rAbs were produced: CR23003, CR23004, and CR23005 (from a patient vaccinated with Jcovden, Johnson & Johnson-Janssen (Beerse, Belgium)), CR22046, and CR22050 and CR22066 (from two different patients vaccinated with Vaxzevria, AstraZeneca (Cambridge, UK)). These rAbs were further characterized using anti-PF4 and anti-PF4/heparin IgG ELISAs, rapid anti-PF4 and anti-PF4/polyanion chemiluminescence assays, and PF4-induced platelet activation assay (PIPA) and their capacity to induce procoagulant platelets. …”
Get full text

Signature for Pain Recovery IN Teens (SPRINT): protocol for a multisite prospective signature study in chronic musculoskeletal pain by Fiona Campbell, Jennifer Stinson, Sara E Williams, Christopher D King, Laura Simons, Massieh Moayedi, Robert C Coghill, Martin S Angst, Nima Aghaeepour, Brice Gaudilliere, Marina López-Solà, Marie-Eve Hoeppli, Emma Biggs, Ed Ganio, Kenneth R Goldschneider, Danielle Ruskin, Elliot J Krane, Suellen Walker, Gillian Rush, Marissa Heirich

Get full text

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context by Abha A. Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte, Eric W. Winquist, Quincy Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyżanowska, Christine Elser, Sebastien Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey

“…Interpretation: Durvalumab + tremelimumab treatment resulted in meaningful responses in salivary carcinoma and CCCO and deserves further exploration in front-line studies. Funding: AstraZeneca and Canadian Cancer Society.…”
Get full text

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch re... by Heather Lin, Vivek Subbiah, Siqing Fu, Aung Naing, Courtney Nicholas, Shubham Pant, Chad Tang, Michael A Curran, David S Hong, Ying Yuan, Sarina A Piha-Paul, Jordi Rodon Ahnert, Timonthy A Yap, Apostolia M Tsimberidou, Daniel D Karp, Anupallavi Srinivasamani, Coline Couillault, Genevieve P Hartley, James Dai, Ecaterina E Ileana Dumbrava, Paola Guerrero, Sarah Dhebat, Theresa Proia

Get full text

Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting by Martina A. McAteer, Daniel R. McGowan, Gary J. R. Cook, Hing Y. Leung, Tony Ng, James P. B. O’Connor, Luigi Aloj, Anna Barnes, Phil J. Blower, Kevin M. Brindle, John Braun, Craig Buckley, Daniel Darian, Paul Evans, Vicky Goh, David Grainger, Carol Green, Matt G. Hall, Thomas A. Harding, Catherine D. G. Hines, Simon J. Hollingsworth, Penny L. Hubbard Cristinacce, Rowland O. Illing, Martin Lee, Baptiste Leurent, Sue Mallett, Radhouene Neji, Natalia Norori, Nora Pashayan, Neel Patel, Kieran Prior, Thomas Reiner, Adam Retter, Alasdair Taylor, Jasper van der Aart, Joseph Woollcott, Wai-Lup Wong, Jan van der Meulen, Shonit Punwani, Geoff S. Higgins

Get full text

Effect of Bacille Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2 and COVID‐19 vaccination by Nicole L Messina, Susie Germano, Amy W Chung, Carolien E van deSandt, Natalie E Stevens, Lilith F Allen, Rhian Bonnici, Julio Croda, Claudio Counoupas, Branka Grubor‐Bauk, Ebene R Haycroft, Katherine Kedzierska, Ellie McDonald, Rebecca McElroy, Mihai G Netea, Boris Novakovic, Kirsten P Perrett, Laure F Pittet, Ruth A Purcell, Kanta Subbarao, James A Triccas, David J Lynn, Nigel Curtis, the BRACE Trial Consortium Group

“…Methods Blood samples, from a subset of 275 SARS‐CoV‐2‐naïve healthcare workers randomised to BCG vaccination (BCG group) or no BCG vaccination (Control group) in the BRACE trial, were collected before and 28 days after the primary course (two doses) of ChAdOx1‐S (Oxford‐AstraZeneca) or BNT162b2 (Pfizer‐BioNTech) vaccination. …”
Get full text